Navigation Links
HCV Patients Survival After Liver Transplantation is Not Improving

For liver transplant recipients without hepatitis C (HCV), survival has improved over time. However, for recipients with HCV, survival has not improved , according to a study in the issue of Liver Transplantation.

HCV-induced liver disease is the most common reason for liver transplantation in the U.S., however, previous studies have shown that these patients do not respond as well to liver transplantation. The difference has become even more striking in recent years, leading some to suggest that survival rates have been decreasing for patients with HCV who have received transplants.

Researchers led by Paul Thuluvath of The Johns Hopkins School of Medicine in Baltimore, MD, sought to study a large sample of the liver transplant population to determine if there has indeed been a decline in survival among HCV patients after adjusting for possible confounding factors.

They gathered data from the United Network for Organ Sharing on all adult liver transplantation performed in the U.S. between January 1991 and October 2001. They included 5,708 HCV patients and 16,116 non-HCV patients and performed multivariate analysis to determine the impact of confounding factors on survival.

The proportion of liver transplant patients with HCV increased dramatically over the study time period, from 16.4 percent in 1991 to 54.7 percent in 2001. However, patients with HCV had a lower 3-year survival (78.5 percent) compared to non-HCV patients (81.7 percent.) For the former group, there was no improvement in survival during the study period, in contrast to the latter group.

"In summary, the survival of patients transplanted with HCV is significantly lower than those without HCV," the authors report. "There has been a statistically significant improvement in patient and graft survival for non-HCV recipients between 1991 and 2001, but for HCV recipients, the survival rate has remained unchanged without any obvious exp
'"/>




Page: 1 2

Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Amphetamines Help Recovery of Stroke Patients
3. Painkillers Do Not Shorten Dying Patients Lives
4. Patients With Filariasis More Prone To HIV Infection
5. Glivec - New Hope For CMC Patients
6. Patients often assume wrongly that they are allergic to penicillin
7. New FDA Approved Drug NATRECOR For Heart Failure Patients
8. Hemochromatosis Patients Blood is Safe
9. Patients Pressure Would Result In Overprescription
10. Risk Of Decongestants In Hypertensive Patients
11. Interference helps Heart Patients
Post Your Comments:
Breaking Medicine News(10 mins):Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 2Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 3Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 2Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 3Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 4Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 5Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 6Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 7Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 8Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 9Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 10Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 11Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 2Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 3Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 4Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 5Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 6Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 7Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 8Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 9Health News:Prescient Medical, Inc. CEO Patricia Scheller to Speak at 'The Value of Innovation in Health Care,' a Galen Institute Conference 2Health News:Help Young Cancer Patients Enjoy Christmas This Season 2
Breaking Medicine Technology:Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5The Worlds Only Online Marketplace Dedicated to Buying and Selling Gently Used and New Special Needs Equipment 3A DifferentNeedz com 5284 1The Worlds Only Online Marketplace Dedicated to Buying and Selling Gently Used and New Special Needs Equipment 3A DifferentNeedz com 5284 2Marc J Fagel of the U S Securities and Exchange Commission to Discuss SEC Enforcement at CBIs Biotech Pharma Finance and Accounting Forum in San Fra 5282 1Marc J Fagel of the U S Securities and Exchange Commission to Discuss SEC Enforcement at CBIs Biotech Pharma Finance and Accounting Forum in San Fra 5282 2Mike Fuljenz and Universal Coin 26amp 3B Bullion Sponsors the NRA Eddie Eagle GunSafe Program 14381 1Mike Fuljenz and Universal Coin 26amp 3B Bullion Sponsors the NRA Eddie Eagle GunSafe Program 14381 2